Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNA043 in Articular Cartilage Lesions and Knee Osteoarthritis
NCT03275064Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2017
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of LNA043 in articular cartilage lesion, osteoarthritis (OA), sponsored by Novartis. Started Sep 2017; status: completed.
02
Drugs
LNA043
03
Conditions
articular cartilage lesionosteoarthritis (OA)
Beyond the preview
Go deeper on NCT03275064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275064.